Indonesia Pravastatin to Prevent Preeclampsia Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

280 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-03-01

Study Completion Date

2020-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

BACKGROUND Preeclampsia is a major cause of maternal and neonatal morbidity worldwide. There is currently no cure for preeclampsia, the only definitive treatment is termination of pregnancy by induction of labour or caesarean section. Statin has been proposed to represent a new approach to improve disease outcome/prevent preeclampsia based on its multilayered activity toward pregnancy protection, including: protection of vascular endothelial cells survival, induce expression of heme oxygenase 1 (HO-1), inhibiting the release of soluble FMS-like tirosine kinase-1 (sFlt-1) and soluble endoglin (sEng), two main culprits in the pathophysiology of preeclampsia.

OBJECTIVE The aim of this study is to observe the effect of pravastatin administration in patients with high risk of preeclampsia in order to reduce maternal and neonatal mortality and morbidity.

METHODS This is a prospective randomized controlled clinical trial. The research will be held in 5 maternal fetal medicine centers in Indonesia (multicenter study). The recruitment will be done by permuted block random sampling methods, with sample size around 280 patients divides into two group. Patients with high risk of preeclampsia will be randomized either to get pravastatin 2 x 20 mg per oral and aspirin 1 x 80 mg (treatment group) or low dose aspirin only (control group). The patient will be followed regularly until delivery to obtain detailed maternal and neonatal outcome.

OUTCOME Primary Outcomes: Maternal preeclampsia, severe preeclampsia, gestational hypertension, indicated preterm delivery less than 37 weeks, indicated preterm delivery less than 34 weeks, maternal complications, length of hospital stay, and any serious adverse event.

Secondary Outcomes: Composite fetal/neonatal mortality and morbidity (stillbirth, neonatal death, respiratory distress syndrome, intracerebral hemorrhage, neonatal sepsis, intra uterine growth restriction \[Small for Gestational Age (SGA) \< 5th centile\], and necrotizing enterocolitis), birthweight, birthweight percentile, level of care (well baby, intermediate, NICU), NICU length of stay, ventilator usage, and length of perinatal hospital stay.

KEYWORDS: pravastatin, preeclampsia, neonatal mortality, neonatal morbidity

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pravastatin to Prevent Preeclampsia

NCT03944512

Preeclampsia Obstetric Labor Complications Hypertension in Pregnancy

TERMINATED PHASE3

Pravastatin for Prevention of Preeclampsia

NCT01717586

Preeclampsia

COMPLETED PHASE1

Sensitivity of Angiotensin II Type II Receptors in Women Following Preeclampsia

NCT05937841

Preeclampsia Postpartum

RECRUITING EARLY_PHASE1

Losartan for Improved Vascular Endothelial Function After Preeclampsia

NCT04632589

Preeclampsia Postpartum

COMPLETED EARLY_PHASE1

Oral Prophylactic Measures on the Occurrence of Pre-eclampsia (OP-PE)

NCT04989075

Pregnancy Complications

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pre-Eclampsia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Multicenter Randomized Non Blinded Trial comparing low dose aspirin versus low dose aspirin and pravastatin in patients with high risk developing preeclampsia

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Outcome Assessors

The diagnosis is made by resident unaware of the medication patients received

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pravastatin Treatment Group

In this arm, the participant will be given aspirin 80 mg daily per oral and the study drugs, Pravastatin 2 x 20 mg per oral daily.

Group Type EXPERIMENTAL

Pravastatin

Intervention Type DRUG

The participant will be given pravastatin 2 x 20 mg per oral daily

Control Group

In this arm, the participant will be given aspirin 80 mg daily per oral and the study drugs, Pravastatin 2 x 20 mg per oral daily.

In this arm, the participant will be given aspirin 80 mg daily per oral, as it already a standard protocol for the high risk preeclampsia group

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pravastatin

The participant will be given pravastatin 2 x 20 mg per oral daily

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Pravastatin Sodium

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Gestational Age 10 wk - 19 wk 6 day
* History of previous preeclampsia requiring birth \< 37 weeks (risk 30%), or
* Patients with a combination of at least 2 major risk factors plus an abnormal uterine artery Doppler at 11-20 weeks gestation (risk preeclampsia 30%):

* Major clinical risk factors (Obesity, strong family history of preeclampsia \[mother or sister\], maternal age \> 40 years old, chronic hypertension, Policystic Ovarian Syndrome (PCOS), Chronic kidney disease, diabetes mellitus, multiple pregnancies, first pregnancy, pregnancy interval more than 10 years, new partner/husband, Reproductive technologies (IVF pregnancy), heritable thrombophilias, Booking Blood pressure \>130/80 mmHg, family history of early onset cardiovascular disease, lower socioeconomic status)
* Abnormal uterine artery Doppler defined as (Second trimester screening:

average resistance index \> 0.58 and/or or early-diastolic diastolic notch. First trimester screening: Pulsatility index \> 95th centile or PI \> 1.5) or:

* First trimester screening (11+0 to 14+1 weeks): Combination of maternal risk factors, elevated MAP, and increased Uterine artery pulsatility index (UTPI).
* Second trimester screening (19+0 to 24+6 weeks): Combination of maternal risk factors, elevated MAP, and increased Uterine artery pulsatility index (UTPI).
* Combination of elevated mean arterial pressure (MAP \> 90 mmHg) in the second trimester with abnormal uterine artery Doppler
* Combination elevated booking blood pressure (\> 130/85 mmHg) with abnormal uterine artery Doppler
* Live fetus, no detectable fetal anomaly

Exclusion Criteria

* Condition where the pregnancies should be terminated within 48 hours, on the basis of any indication (patients consume pravastatin less than 2 days).
* Contraindication to the statin use:

* Hypersensitivity to pravastatin
* Active liver disease
* Pre pregnant renal insufficiency/kidney failure (history of hemodialysis)
* Current use of statin
* Participation in any other controlled trial of investigational medical products in pregnancy

Minimum Eligible Age

15 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Muhammad Ilham Aldika Akbar, MD, OBGYN

Principal Investigator, MFM Consultant

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Muhammad Ilham Aldika Akbar, MD, OBGYN

Role: PRINCIPAL_INVESTIGATOR

Universitas Airlangga

Locations

Explore where the study is taking place and check the recruitment status at each participating site.